Detalhe da pesquisa
1.
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Eur J Neurol
; 24(5): 726-733, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-28328179
2.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
N Engl J Med
; 367(12): 1087-97, 2012 Sep 20.
Artigo
Inglês
| MEDLINE | ID: mdl-22992072
3.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Mult Scler
; 21(1): 57-66, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24990854
4.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Mult Scler
; 20(2): 253-7, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24150778
5.
BG-12 in multiple sclerosis.
Semin Neurol
; 33(1): 56-65, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23709213
6.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Mult Scler
; 17(8): 970-9, 2011 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-21421809
7.
An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
BMC Neurol
; 11: 126, 2011 Oct 14.
Artigo
Inglês
| MEDLINE | ID: mdl-21999176
8.
Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data.
Nat Commun
; 12(1): 4385, 2021 07 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34282143
9.
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Lancet Neurol
; 8(3): 254-60, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19201654
10.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med
; 354(9): 899-910, 2006 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-16510744
11.
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.
Neurol Ther
; 8(1): 109-119, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30706431
12.
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Neurology
; 92(15): e1724-e1738, 2019 04 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30918100
13.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Ann Neurol
; 62(4): 335-46, 2007 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17696126
14.
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Arch Neurol
; 64(2): 169-76, 2007 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-17296831
15.
Dimethyl Fumarate: A Review of Efficacy and Practical Management Strategies for Common Adverse Events in Patients with Multiple Sclerosis.
Int J MS Care
; 19(2): 74-83, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-32607065
16.
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
Neurol Ther
; 6(2): 175-187, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28770420
17.
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Clin Ther
; 39(8): 1671-1679, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28751099
18.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Arch Neurol
; 63(10): 1383-7, 2006 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17030653
19.
Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices.
Neurol Clin Pract
; 6(4): 329-338, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27574570
20.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Neurol Ther
; 5(1): 45-57, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-26932146